Abstract

Trichomonas vaginalis is the causative agent of trichomoniasis, the most prevalent non-viral sexually transmitted infection worldwide. Metronidazole (MTZ) is the mainstay of anti-trichomonal chemotherapy; however, drug resistance has become an increasingly worrying issue. Additionally, the molecular events of MTZ-induced cell death in T. vaginalis remain elusive. To gain insight into the differential expression of genes related to MTZ resistance and cell death, we conducted RNA-sequencing of three paired MTZ-resistant (MTZ-R) and MTZ-sensitive (MTZ-S) T. vaginalis strains treated with or without MTZ. Comparative transcriptomes analysis identified that several putative drug-resistant genes were exclusively upregulated in different MTZ-R strains, such as ATP-binding cassette (ABC) transporters and multidrug resistance pumps. Additionally, several shared upregulated genes among all the MTZ-R transcriptomes were not previously identified in T. vaginalis, such as 5′-nucleotidase surE and Na+-driven multidrug efflux pump, which are a potential stress response protein and a multidrug and toxic compound extrusion (MATE)-like protein, respectively. Functional enrichment analysis revealed that purine and pyrimidine metabolisms were suppressed in MTZ-S parasites upon drug treatment, whereas the endoplasmic reticulum-associated degradation (ERAD) pathway, proteasome, and ubiquitin-mediated proteolysis were strikingly activated, highlighting the novel pathways responsible for drug-induced stress. Our work presents the most detailed analysis of the transcriptional changes and the regulatory networks associated with MTZ resistance and MTZ-induced signaling, providing insights into MTZ resistance and cell death mechanisms in trichomonads.

Highlights

  • The protozoan parasite Trichomonas vaginalis is the causative agent of human trichomoniasis and annually infects approximately 276 million people worldwide [1]

  • We found that several genes were solely upregulated in the MTZ-R Tv-50142 strain, including ABC transporters (TVAG_162060 and TVAG_024550), multidrug resistance (MDR) pump (TVAG_369180), MdaB (TVAG_091830), and leucine-rich repeat proteins, BspA family, whereas these genes were nearly not expressed in the other MTZ-S or MTZ-R strains

  • MTZ-R and MTZ-S strains in the presence or absence of MTZ, identifying strain-specific and common genes associated with MTZ resistance at the isoform level

Read more

Summary

Introduction

The protozoan parasite Trichomonas vaginalis is the causative agent of human trichomoniasis and annually infects approximately 276 million people worldwide [1]. T. vaginalis colonizes the urogenital tract of humans and mainly leads to vaginal discharge, pruritus, odor, and irritation in women [2]. The complications of trichomoniasis are accompanied by severe health consequences, such as cervical cancer [3], adverse pregnancy outcomes [4], infertility [5], and human immunodeficiency virus (HIV) transmission [6]. Men are often asymptomatic carriers of T. vaginalis, dysuria, discharge, and increased risk of prostate cancer have been reported [7]. The nitroimidazole drug family, represented by MTZ and tinidazole (TNZ), is the only class of drugs currently approved by the Food and Drug Administration for the treatment of trichomoniasis. The reliance on a single therapeutic class is problematic, since MTZ-R isolates are on the rise [8,9]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call